Finding 975064 (2023-001)

Material Weakness Repeat Finding
Requirement
I
Questioned Costs
-
Year
2023
Accepted
2024-05-29

AI Summary

  • Core Issue: The organization lacks a written procurement policy required by federal regulations.
  • Impacted Requirements: Noncompliance with Title 2, Subtitle A, Chapter 2 Part 200, Subpart D, section 200.318 of the Code of Federal Regulations.
  • Recommended Follow-Up: Develop and implement a compliant procurement policy by 2024.

Finding Text

Federal Agency: Department of Health and Human Services Federal Program: Research and Development Cluster Assistance Listing Number: 93.847, 93.867, & 93.103 Federal Award Identification Number and Year: Various Award Period: January 1, 2023, through December 31, 2023 Type of Finding: Other Matters Finding related to Compliance within Uniform Guidance and Material Weakness in Internal Control Over Compliance Criteria or specific requirement: Title 2, Subtitle A, Chapter 2 Part 200, Subpart D, section 200.318 of the Code of Federal Regulations requires organizations to have a written procurement policy that includes certain requirements as it relates to procuring goods and services using federal dollars. Condition: During our testing, it was noted that the Organization does not have a written procurement policy in place that covers the requirements noted in Section 200.318 of the Code of Federal Regulations. Questioned costs: None Context: The new policy was being developed during 2023 Cause: The new policy was not put in place until 2024 Effect: Noncompliance with federal procurement requirements Repeat Finding: Yes, 2022-002 Recommendation: We recommend that the Organization develop a written procurement policy that meets the requirements noted in Section 200.318 of the Code of Federal Regulations. Views of responsible officials and Planned Corrective Actions: There is no disagreement with the audit finding. See Corrective Action Plan prepared by the Organization.

Categories

Procurement, Suspension & Debarment Material Weakness Internal Control / Segregation of Duties

Other Findings in this Audit

  • 398619 2023-001
    Material Weakness Repeat
  • 398620 2023-001
    Material Weakness Repeat
  • 398621 2023-001
    Material Weakness Repeat
  • 398622 2023-001
    Material Weakness Repeat
  • 398623 2023-001
    Material Weakness Repeat
  • 398624 2023-001
    Material Weakness Repeat
  • 398625 2023-001
    Material Weakness Repeat
  • 398626 2023-001
    Material Weakness Repeat
  • 398627 2023-001
    Material Weakness Repeat
  • 975061 2023-001
    Material Weakness Repeat
  • 975062 2023-001
    Material Weakness Repeat
  • 975063 2023-001
    Material Weakness Repeat
  • 975065 2023-001
    Material Weakness Repeat
  • 975066 2023-001
    Material Weakness Repeat
  • 975067 2023-001
    Material Weakness Repeat
  • 975068 2023-001
    Material Weakness Repeat
  • 975069 2023-001
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $1.18M
93.867 Vision Research $128,694
93.103 Food and Drug Administration_research $41,537